{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:10:08Z","timestamp":1793387408346,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Janssen Pharmaceutical Companies of Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:53:19Z","timestamp":1741899199000},"page":"104-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers"],"prefix":"10.1016","volume":"93","author":[{"given":"Jonas","family":"Banefelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Skr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlem","family":"Azzabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Suruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geldhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.03.016_bib2","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/bjd.12002","article-title":"Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies","volume":"167","author":"Xu","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.016_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"24","key":"10.1016\/j.jaad.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaad.2025.03.016_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcme.2015.01.005","article-title":"Psoriasis and cardiovascular risk: immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation","volume":"6","author":"K\u00f6lliker Frers","year":"2015","journal-title":"IJC Metab Endocr"},{"issue":"12","key":"10.1016\/j.jaad.2025.03.016_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.autrev.2011.05.022","article-title":"Atherosclerosis in psoriatic arthritis","volume":"10","author":"Ramonda","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"13","key":"10.1016\/j.jaad.2025.03.016_bib9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.016_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.016_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.016_bib12","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jdv.14951","article-title":"Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.03.016_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.jaad.2025.03.016_bib14","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.016_bib15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.016_bib16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.jaad.2025.03.016_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.016_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamadermatol.2020.4456","article-title":"Association between early severe cardiovascular events and ustekinumab treatment?","volume":"157","author":"Gelfand","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.016_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.016_bib20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.03.016_bib21","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2025.03.016_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.016_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"Jama"},{"key":"10.1016\/j.jaad.2025.03.016_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jaad.2025.03.016_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.016_bib26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2025.03.016_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jaad.2025.03.016_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"9596","key":"10.1016\/j.jaad.2025.03.016_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.jaad.2025.03.016_bib30","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jaad.2025.03.016_bib31","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.016_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.jaad.2025.03.016_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.016_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100226","article-title":"Concepts of designing and implementing pharmacoepidemiology studies on the safety of systemic treatments in dermatology practice","volume":"3","author":"Schneeweiss","year":"2023","journal-title":"JID Innov"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.016_bib35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.016_bib37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.016_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jdv.16018","article-title":"Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study","volume":"34","author":"Rungapiromnan","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.03.016_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:44:45Z","timestamp":1766112285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225004347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225004347"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.016","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}